These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 19179558)

  • 1. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
    Blackwell KL; Pegram MD; Tan-Chiu E; Schwartzberg LS; Arbushites MC; Maltzman JD; Forster JK; Rubin SD; Stein SH; Burstein HJ
    Ann Oncol; 2009 Jun; 20(6):1026-31. PubMed ID: 19179558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.
    Crown J; Kennedy MJ; Tresca P; Marty M; Espie M; Burris HA; DeSilvio M; Lau MR; Kothari D; Koch KM; Diéras V
    Ann Oncol; 2013 Aug; 24(8):2005-11. PubMed ID: 23878115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.
    Burstein HJ; Storniolo AM; Franco S; Forster J; Stein S; Rubin S; Salazar VM; Blackwell KL
    Ann Oncol; 2008 Jun; 19(6):1068-74. PubMed ID: 18283035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
    Montemurro F; Prat A; Rossi V; Valabrega G; Sperinde J; Peraldo-Neia C; Donadio M; Galván P; Sapino A; Aglietta M; Baselga J; Scaltriti M
    Mol Oncol; 2014 Feb; 8(1):20-6. PubMed ID: 24075779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
    Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
    Blackwell KL; Burstein HJ; Storniolo AM; Rugo H; Sledge G; Koehler M; Ellis C; Casey M; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
    J Clin Oncol; 2010 Mar; 28(7):1124-30. PubMed ID: 20124187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
    Kaufman B; Trudeau M; Awada A; Blackwell K; Bachelot T; Salazar V; DeSilvio M; Westlund R; Zaks T; Spector N; Johnston S
    Lancet Oncol; 2009 Jun; 10(6):581-8. PubMed ID: 19394894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
    Gori S; Montemurro F; Spazzapan S; Metro G; Foglietta J; Bisagni G; Ferzi A; Silva RR; Gamucci T; Clavarezza M; Stocchi L; Fabi A; Cognetti F; Torrisi E; Crivellari D
    Ann Oncol; 2012 Jun; 23(6):1436-41. PubMed ID: 22039084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
    Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
    Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
    Falchook GS; Moulder SL; Wheler JJ; Jiang Y; Bastida CC; Kurzrock R
    Ann Oncol; 2013 Dec; 24(12):3004-11. PubMed ID: 24158411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of lapatinib in HER2-positive breast cancer.
    Ulhoa-Cintra A; Greenberg L; Geyer CE
    Curr Oncol Rep; 2008 Jan; 10(1):10-7. PubMed ID: 18366956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
    Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
    J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
    Toi M; Iwata H; Fujiwara Y; Ito Y; Nakamura S; Tokuda Y; Taguchi T; Rai Y; Aogi K; Arai T; Watanabe J; Wakamatsu T; Katsura K; Ellis CE; Gagnon RC; Allen KE; Sasaki Y; Takashima S
    Br J Cancer; 2009 Nov; 101(10):1676-82. PubMed ID: 19844234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
    Dave B; Migliaccio I; Gutierrez MC; Wu MF; Chamness GC; Wong H; Narasanna A; Chakrabarty A; Hilsenbeck SG; Huang J; Rimawi M; Schiff R; Arteaga C; Osborne CK; Chang JC
    J Clin Oncol; 2011 Jan; 29(2):166-73. PubMed ID: 21135276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.